Jason M Lepree

US Patent:

20110263720, Oct 27, 2011

Filed:

Mar 9, 2011

Appl. No.:

13/044056

Inventors:

Steven D. PAISLEY - Danbury CT, US
Jason M. LePree - Demarest NJ, US
Amale Hawi - Ridgefield CT, US
Michael Eckhoff - Ridgefield CT, US

Assignee:

Penwest Pharmaceuticals Co. - Patterson NY

International Classification:

A61K 31/122
C07C 49/497
A61P 25/00
A61P 3/10
A61P 25/28
A61P 25/18
A61P 35/00
C07C 45/60
A61P 25/08

US Classification:

514678, 568323, 568308

Abstract:

The present invention is directed to a method of synthesizing a compound of Formula I:the method comprising oxidizing alpha-tocopherol with a metal salt oxidizing agent to form the compound of Formula I, wherein the stoichiometric ratio (mol/mol) of metal salt oxidizing agent/alpha-tocopherol is 1.6 to 4. The invention is also directed to a method of synthesizing a compound of Formula I, the method comprising (a) hydrolyzing alpha-tocopheryl acetate in the presence of a base; (b) neutralizing the hydrolyzing of (a), thereby forming alpha-tocopherol; and (c) oxidizing the alpha-tocopherol of (b) with a metal salt oxidizing agent to form the compound of Formula I, wherein the stoichiometric ratio (mol/mol) of metal salt oxidizing agent/alpha-tocopherol is 1.6 to 4.

US Patent:

20170196802, Jul 13, 2017

Filed:

Aug 12, 2016

Appl. No.:

15/235763

Inventors:

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Jason LePREE - Demarest NJ, US
Hetalben PRAJAPATI - New Milford NJ, US
Tahseen A. CHOWDHURY - Washington-Township NJ, US

Assignee:

Abon Pharmaceuticals, LLC - Northvale NJ

International Classification:

A61K 9/00
A61K 31/496
A61K 47/26
A61K 47/22
A61K 47/10
A61K 31/5415
A61K 31/675
A61K 47/14
A61K 47/44

Abstract:

The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C-Cfatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a Dparticle size of about 0.5 μm to about 25 μm in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25 C.

US Patent:

20170196855, Jul 13, 2017

Filed:

Oct 24, 2016

Appl. No.:

15/332592

Inventors:

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Jason LePREE - Demarest NJ, US
Hetalben PRAJAPATI - New Milford NJ, US
Tahseen A. CHOWDHURY - Washington-Township NJ, US

Assignee:

Abon Pharmaceuticals, LLC - Northvale NJ

International Classification:

A61K 31/496
A61K 47/26
A61K 47/44
A61K 47/34
A61K 47/22
A61K 47/10
A61K 31/675
A61K 9/00
A61K 47/20
A61K 31/495
A61K 9/08
A61K 31/5415

Abstract:

The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 μm to about 25 μm in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25 C.